Ginkgo BioWorks has been granted a patent for gene therapy compositions and methods to treat NPC1 using Adeno-associated virus (AAV) vectors. The patent includes a specific AAV vector design with a sequence of capsid protein subunit and a transfer cassette encoding NPC1 protein. GlobalData’s report on Ginkgo BioWorks gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights Ginkgo BioWorks Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Ginkgo BioWorks, was a key innovation area identified from patents. Ginkgo BioWorks's grant share as of February 2024 was 49%. Grant share is based on the ratio of number of grants to total number of patents.

Aav vector for treating npc1 with specific gene sequence

Source: United States Patent and Trademark Office (USPTO). Credit: Ginkgo BioWorks Inc

A recently granted patent (Publication Number: US11905523B2) discloses an adeno-associated virus (AAV) vector designed for gene therapy applications. The vector comprises a protein capsid with a specific capsid protein subunit sequence and encapsulates a nucleic acid containing a transfer cassette. This transfer cassette includes elements such as inverted terminal repeats, a promoter, a transgene encoding a Niemann-Pick intracellular cholesterol transporter 1 (NPC1) protein, a polyadenylation signal, and intronic sequences. The vector is further characterized by the presence of specific sequences for the ITRs, promoter, NPC1 protein, and polyadenylation signal.

The patent also covers compositions and methods utilizing this AAV vector for treating conditions such as Neimann-Pick Disease Type C in human subjects. The method involves administering the AAV vector to the subject to deliver the therapeutic transgene encoding the NPC1 protein. The inclusion of specific sequences and elements in the vector, such as the CBA promoter and SV40 polyadenylation signal, enhances its efficacy in gene therapy applications. Overall, this patented AAV vector presents a promising approach for treating genetic disorders like Neimann-Pick Disease Type C in human patients, highlighting the potential of gene therapy in addressing rare and debilitating conditions.

To know more about GlobalData’s detailed insights on Ginkgo BioWorks, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies